MTHFR polymorphism: ~10% population homozygous for MTHFR C677T — reduced conversion to active 5-MTHF. Unmetabolised folic acid (UMFA) accumulation at high doses — unknown health significance. Mask B12 deficiency: high folic acid masks haematological signs of B12 deficiency while neurological damage continues. Drug interactions: methotrexate (antifolate drug — do not co-supplement without oncologist guidance), anticonvulsants (reduce folate levels).
Synthetic oxidised form of folate. Metabolically less direct than natural folates or 5-MTHF. Critical for neural tube defect prevention in pregnancy. MTHFR variants may limit conversion.
Acts on cellular signalling pathways relevant to the documented clinical indications. Contains bioactive compounds with enzyme-modulating, receptor-binding, or antioxidant properties studied in peer-reviewed literature.
| Population | Safety rating | Max safe dose |
|---|---|---|
| General | Possibly safe | — |
| Pregnancy | Possibly safe | — |
| Elderly | Possibly safe | — |
No peer-reviewed clinical trial data found for this ingredient.
Data by supplement.ge — Public Health Institute of Georgia (PHIG)